Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Trevi Therapeutics, Inc. (TRVI)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
2 days ago | PRNewsWire
5 days ago | PRNewsWire
a week ago | PRNewsWire
2 months ago | PRNewsWire
3 months ago | PRNewsWire
3 months ago | PRNewsWire
4 months ago | GlobeNewsWire
Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
4 months ago | GlobeNewsWire
4 months ago | GlobeNewsWire
6 months ago | Zacks Investment Research
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It develops Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease, as well as to treat chronic kidney disease-associated with pruritus. The company was founded in 2011 and is headquartered in New Haven, Connecticut.
Sector:
HealthcareIndustry:
BiotechnologyEmployees:
22Address:
Trevi Therapeutics, Inc. 195 Church Street 14th Floor New Haven CT 06510 United StatesWebsite:
Home